Anti-Muellerian hormone
| GO Term | Evidence Code | Reference |
|---|---|---|
| ovarian follicle development | ||
| preantral ovarian follicle growth | ||
| urogenital system development |
|
|
| Mullerian duct regression | ||
| Mullerian duct regression |
| GO Term | Evidence Code | Reference |
|---|---|---|
| extracellular region | ||
| extracellular region | ||
| extracellular region | ||
| extracellular region | ||
| extracellular region |
| GO Term | Evidence Code | Reference |
|---|---|---|
| signaling receptor binding | ||
| type II transforming growth factor beta receptor binding | ||
| transforming growth factor beta receptor binding | ||
| transforming growth factor beta receptor binding | ||
| hormone activity |
| Pathway Name | Organism |
|---|---|
| Signaling by BMP | Homo sapiens |
| Transcriptional regulation of testis differentiation | Homo sapiens |
| DO ID | Disease Name | Source |
|---|---|---|
| DOID:1923 | disorder of sexual development | |
| DOID:0050791 | persistent Mullerian duct syndrome | |
| DOID:4001 | ovarian carcinoma |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.5.0
Last updated: April 6, 2026